Comparing Fulcrum Therapeutics (NASDAQ:FULC) and InflaRx (NASDAQ:IFRX)
by Danessa Lincoln · The Markets DailyInflaRx (NASDAQ:IFRX – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Valuation and Earnings
This table compares InflaRx and Fulcrum Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InflaRx | $30,000.00 | 9,849.23 | -$51.63 million | ($0.58) | -3.46 |
| Fulcrum Therapeutics | $80.00 million | 3.61 | -$74.88 million | ($1.21) | -3.13 |
InflaRx has higher earnings, but lower revenue than Fulcrum Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
InflaRx has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for InflaRx and Fulcrum Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InflaRx | 1 | 2 | 5 | 1 | 2.67 |
| Fulcrum Therapeutics | 4 | 7 | 1 | 0 | 1.75 |
InflaRx currently has a consensus target price of $7.43, suggesting a potential upside of 270.50%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 116.64%. Given InflaRx’s stronger consensus rating and higher probable upside, equities research analysts plainly believe InflaRx is more favorable than Fulcrum Therapeutics.
Institutional & Insider Ownership
42.4% of InflaRx shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares InflaRx and Fulcrum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InflaRx | N/A | -53.56% | -43.02% |
| Fulcrum Therapeutics | N/A | -25.38% | -24.15% |
Summary
InflaRx beats Fulcrum Therapeutics on 8 of the 14 factors compared between the two stocks.
About InflaRx
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.